Literature DB >> 31559550

In Vitro Anti-hepatoma Activities of Notoginsenoside R1 Through Downregulation of Tumor Promoter miR-21.

Yuan Li1, Zhong Li1, Yunhao Jia1, Bo Ding1, Jinsong Yu2.   

Abstract

BACKGROUND: Notoginsenoside R1 (NG-R1) is the predominant active ingredient and a novel triterpene saponin compound extracted from the roots of Panax notoginseng. To date, to the best of our knowledge, there are no previous studies concerning the effect of NG-R1 on hepatocellular carcinoma (HCC). AIMS: To investigate the effects of NG-R1 on HCC cell growth, apoptosis, and invasion and to explore the underlying mechanisms.
METHODS: Cell viability and lactate dehydrogenase (LDH) release were evaluated by cell counting kit-8 and LDH assay, respectively. Apoptosis was assessed using flow cytometry analysis and caspase-3/7 activity assay. Cell invasion was detected by Transwell invasion assay and western blot analysis of matrix metallopeptidase (MMP)-2 and MMP-9. The effects of NG-R1 on miR-21 expression and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway were examined by qRT-PCR and western blot, respectively.
RESULTS: NG-R1 inhibited the viability, increased LDH release and caspase-3/7 activity, induced apoptosis, and suppressed invasion in HCC cells. NG-R1 reduced miR-21 expression in HCC cells. miR-21 overexpression significantly attenuated the effects of NG-R1 on the viability, LDH release, apoptosis, caspase-3/7 activity, and invasion of HCC cells. We further demonstrated that NG-R1 inhibited the activation of the PI3K/Akt pathway in HCC cells, which was abolished by miR-21 overexpression.
CONCLUSIONS: NG-R1 exerted anti-hepatoma activity through inactivation of the PI3K/Akt pathway by downregulating miR-21, contributing to further understanding of the anti-tumor activities of NG-R1 in HCC.

Entities:  

Keywords:  Anti-hepatoma; Hepatocellular carcinoma; Notoginsenoside R1; PI3K/Akt pathway; miR-21

Mesh:

Substances:

Year:  2019        PMID: 31559550     DOI: 10.1007/s10620-019-05856-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

Review 1.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

Review 2.  Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses.

Authors:  Xiang Cheng; Ping Sun; Qing-Gang Hu; Zi-Fang Song; Jun Xiong; Qi-Chang Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-22       Impact factor: 4.553

3.  Anti-carcinogenic activity of the roots of Panax notoginseng. II.

Authors:  T Konoshima; M Takasaki; H Tokuda
Journal:  Biol Pharm Bull       Date:  1999-10       Impact factor: 2.233

4.  Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells.

Authors:  Chong-Zhi Wang; Jing-Tian Xie; Bin Zhang; Ming Ni; Anna Fishbein; Han H Aung; Sangeeta R Mehendale; Wei Du; Tong-Chuan He; Chun-Su Yuan
Journal:  Int J Oncol       Date:  2007-11       Impact factor: 5.650

5.  Panax notoginseng Inhibits Tumor Growth through Activating Macrophage to M1 Polarization.

Authors:  Bosung Kim; Eun-Yeong Kim; Eun-Ji Lee; Jung Ho Han; Chung-Hwan Kwak; Yeon-Seop Jung; Syng-Ook Lee; Tae-Wook Chung; Ki-Tae Ha
Journal:  Am J Chin Med       Date:  2018-08-31       Impact factor: 4.667

6.  RETRACTED: Alkannin inhibits proliferation, migration and invasion of hepatocellular carcinoma cells via regulation of miR-92a.

Authors:  Baozhen Sun; Jingzhe Zhang; Meihan Liu; Lianyue Guan
Journal:  Biomed Pharmacother       Date:  2019-03-22       Impact factor: 6.529

Review 7.  From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.

Authors:  Dimitrios Dimitroulis; Christos Damaskos; Serena Valsami; Spyridon Davakis; Nikolaos Garmpis; Eleftherios Spartalis; Antonios Athanasiou; Demetrios Moris; Stratigoula Sakellariou; Stylianos Kykalos; Gerasimos Tsourouflis; Anna Garmpi; Ioanna Delladetsima; Konstantinos Kontzoglou; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

Review 8.  Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.

Authors:  Kwei-Yan Liu; Li-Ting Wang; Shih-Hsien Hsu
Journal:  Cancers (Basel)       Date:  2018-01-03       Impact factor: 6.639

9.  miR-21 promotes cell migration and invasion of hepatocellular carcinoma by targeting KLF5.

Authors:  Jian Wang; Yanfeng Chu; Mei Xu; Xiumei Zhang; Yumei Zhou; Mei Xu
Journal:  Oncol Lett       Date:  2018-12-18       Impact factor: 2.967

Review 10.  MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy.

Authors:  Ming Hong; Ning Wang; Hor Yue Tan; Sai-Wah Tsao; Yibin Feng
Journal:  Cancers (Basel)       Date:  2015-08-24       Impact factor: 6.639

View more
  4 in total

1.  Notoginsenoside R1 Promotes Migration, Adhesin, Spreading, and Osteogenic Differentiation of Human Adipose Tissue-Derived Mesenchymal Stromal Cells.

Authors:  Haiyan Wang; Yongyong Yan; Haifeng Lan; Nan Wei; Zhichao Zheng; Lihong Wu; Richard T Jaspers; Gang Wu; Janak L Pathak
Journal:  Molecules       Date:  2022-05-25       Impact factor: 4.927

Review 2.  Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases.

Authors:  Hai Liu; Jianqiong Yang; Wanqing Yang; Shaonan Hu; Yali Wu; Bo Zhao; Haiyan Hu; Shouying Du
Journal:  Drug Des Devel Ther       Date:  2020-02-07       Impact factor: 4.162

3.  Notoginsenoside R1 induces DNA damage via PHF6 protein to inhibit cervical carcinoma cell proliferation.

Authors:  Ting Cai; Wenquan Wu; Longhua Guo; Yongwu Xia; Xiaoxin Jiang; Limei Zhang; Feiding Peng; Pinghong Ming
Journal:  Mol Med Rep       Date:  2021-02-04       Impact factor: 2.952

4.  Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling.

Authors:  Minan Lu; Kegong Xie; Xianzhe Lu; Lu Lu; Yu Shi; Yujin Tang
Journal:  Invest New Drugs       Date:  2020-10-30       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.